ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated August 13, 2020.
ICICI Direct's research report on Aurobindo Pharma
Q1FY21 revenues grew 8.8% YoY to Rs 5925 crore (I-direct estimate: Rs 6070 crore) mainly due to 15.6% YoY growth in the US to Rs 3107 crore. EU business de-grew 5.0% YoY to Rs 1322 crore. ARV segment grew 33.6% YoY to Rs 426 crore. API segment grew 6.6% YoY to Rs 780 crore. EBITDA margins remained flat YoY at 21.2% (I-direct estimate: 21.5%) as higher gross margins were offset by higher staff costs and other expenditure. EBITDA grew 9.2% YoY to Rs 1257.4 crore against I-direct estimate of Rs 1304.1 crore. Adjusted PAT grew 20.4% YoY to Rs 780.6 crore (I-direct estimate: Rs 765 crore). Delta vis-à-vis EBITDA was due to lower interest cost and higher other income (including Rs 22.2 crore in forex gain).
We maintain BUY rating and arrive at our revised target price of Rs 1100 at 15x FY22E EPS of Rs 73.2.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.